Inverse correlation between NLRP3 and TMEM176B as a possible tool for colorectal cancer progression
Cambui, R. A.; Roa, M. E.; Leal, V. N.; Yamada, S. M.; de Oliveira, L. A.; Nadaf, I. N.; Leite, C. R.; Pedroso, R. C.; Costa, R. C.; Amorim, R. M.; do Amaral, J. R.; Lemes, P. S.; Rizzo, L. A.; do Espirito Santo, G. F.; Elia, R. M.; Cogliati, B.; Hill, M.; Pontillo, A.
Show abstract
PurposeTMEM176B has been recently identified as a novel player in anti-cancer immune responses by negatively modulating the NLRP3 inflammasome activation in colorectal cancer (CRC). Yet, the TMEM176B/NLRP3 axis in CRC needs to be deeply investigated. MethodsTMEM176B and NLRP3 expression were evaluated in CRC patients by immunohistochemistry and RT-qPCR assays. The prognostic relevance of TMEM176B and NLRP3 was determined by in silico analysis. The NLRP3 inflammasome activation in the CRC microenvironment was assessed in a peripheral blood mononuclear cells (PBMC) and CRC cell line (HCT-116) spheroids co-culture assay. ResultsReduced NLRP3 and increased TMEM176B expression correlates to CRC stages and poor survival. The in vitro assay showed HCT-116 cells activated NLRP3 inflammasome in PBMC. ConclusionThese findings evidence the inverse correlation between NLRP3 and TMEM176B in CRC progression, suggesting them as a predictive tool.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.